Rocket Pharmaceuticals
RCKT
191 hedge funds and large institutions have $1.71B invested in Rocket Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 67 increasing their positions, 53 reducing their positions, and 19 closing their positions.
258% more call options, than puts
Call options by funds: $4.96M | Put options by funds: $1.39M
68% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 19
26% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 53
7% more funds holding
Funds holding: 178 → 191 (+13)
1.35% more ownership
Funds ownership: 100.51% → 101.86% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
13% less capital invested
Capital invested by funds: $1.96B → $1.71B (-$255M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$42.7M |
| 2 |
Millennium Management
New York
|
+$22.5M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$21.8M |
| 4 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
+$7.12M |
| 5 |
State Street
Boston,
Massachusetts
|
+$6.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$20.9M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$17M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$13.7M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$10.9M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$7.19M |
RCKT Hedge Fund Activity: Q3 2024 in Review
191 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q3 2024, worth a combined $1.71B — down 13% from $1.96B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new RCKT positions and 19 closed out — a net gain of 13 holders — while 67 added to existing stakes and 53 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $42.7M. The largest seller was Janus Henderson Group, cutting an estimated $20.9M.
- 191 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q3 2024, up from 178 in Q2 2024.
- Funds reported $1.71B of Rocket Pharmaceuticals stock for Q3 2024, down 13% quarter-over-quarter.
- 32 funds opened new Rocket Pharmaceuticals positions in Q3 2024 and 19 closed out, a net change of +13 holders.
- The largest Rocket Pharmaceuticals buyer in Q3 2024 was Wellington Management Group, an estimated $42.7M added.
- The largest Rocket Pharmaceuticals seller in Q3 2024 was Janus Henderson Group, an estimated $20.9M sold.
Based on aggregated 13F filings for Q3 2024.